Stryker stock gets a CEO succession plan for January 2027

Published on 10/07/2026 at 16:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stryker stock faces a January 1, 2027 CEO handoff as Spencer Stiles succeeds Kevin Lobo. Q2 revenue rose 9.4 percent to USD 6.59 billion and adjusted EPS rose 17.9 percent to USD 3.69.

Trading-Floor mit Händlern und Bildschirmen, die steigende Healthcare-Aktienkurse zeigen — Börsen-Editorial-Foto vom Trading-Floor mit Healthcare-Charts symbolisiert den Aktienhandel von Stryker Corp. US8636671013 an der NYSE, Illustration mit AI erstellt.

Stryker Corporation (ISIN US8636671013) was trading at USD 276.24 on the NYSE on October 7, 2026 at 10:33 a.m. ET, down 0.70 percent from USD 278.20. The medical technology company announced a planned leadership handoff on October 6, with Spencer Stiles set to become CEO on January 1, 2027.

Leadership changes on January 1

According to Stryker on October 6, 2026, current President and Chief Operating Officer Spencer Stiles will succeed Kevin Lobo as chief executive officer and join the board. Lobo will become executive chair after more than 14 years as CEO.

The transition gives Stryker an internal successor with experience across Orthopaedics, MedSurg and Neurotechnology. The company said annual net sales rose from USD 8.7 billion in 2012 to more than USD 26 billion in 2026 during Lobo's tenure, while Stryker completed more than 60 acquisitions.

Q2 revenue rose 9.4 percent

Stryker's latest reported quarter provided a stronger operating comparison. In Q2 2026, revenue reached USD 6.59 billion, up 9.4 percent from the prior-year quarter, while diluted GAAP EPS was USD 3.30, up 44.1 percent, according to MarketBeat.

Adjusted EPS was USD 3.69 in Q2 2026, exceeding the USD 3.49 consensus by USD 0.20. The same quarter produced an adjusted operating margin of 27.4 percent, and management's full-year 2026 adjusted EPS guidance stood at USD 14.95-15.10.

MarketBeat's October 3, 2026 overview showed a Moderate Buy consensus from 19 Buy ratings and five Hold ratings, with an average price target of USD 372.64. That target lies 34.9 percent above the USD 276.24 share price, making analyst expectations a sharper test of execution than the leadership change alone.

Results date meets a weak range

Stryker is scheduled to report Q3 2026 results on October 29, 2026, at 4:05 p.m. ET, according to Simply Wall St. That report will show whether the 9.4 percent Q2 revenue growth and 17.9 percent adjusted EPS growth carried into the second half.

Stryker stock stays near its yearly low

Stryker stock was trading at USD 276.24 on October 7, 2026 on the NYSE. The 52-week range was USD 267.00 to USD 392.55, while market capitalization stood at USD 105.9 billion and volume reached 298,351 shares.